13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001055951
Total reported value
$5.4B
$5.4B
99 檔
23.5%
In Q2 2025, Orbimed Advisors LLC's U.S. equity holdings reached a combined market value of $5.4B, distributed across 99 disclosed stock positions.
In Q2 2025, Orbimed Advisors LLC adopted a defensive or profit-taking posture, trimming 23 positions and completely liquidating 24 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including SVA, BSX, LLY) accounted for 23.5% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SVA | Sinovac Biotech Ltd. | Stock-Other | 8.34% | +3.06% | — | |
| 2 | BSX | Boston Scientific CORP | Stock-Healthcare | 7.55% | -1.88% | — | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.57% | +1.30% | — | |
| 4 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 5.08% | +1.73% | +3.31% | |
| 5 | ELVN | Enliven Therapeutics Inc | Stock-Other | 3.99% | +0.02% | — | |
| 6 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.95% | -0.80% | — | |
| 7 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 3.61% | -0.12% | — | |
| 8 | SYK | Stryker CORP | Stock-Healthcare | 3.55% | -0.30% | — | |
| 9 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 3.34% | -0.61% | +11.49% | |
| 10 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 3.01% | +1.33% | NEW | |
| 11 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.86% | -0.44% | +0.63% | |
| 12 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.78% | -0.71% | -1.21% | |
| 13 | NTRA | Natera Inc | Stock-Healthcare | 2.50% | +0.26% | +8.49% | |
| 14 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.34% | — | +31.51% | |
| 15 | THC | Tenet Healthcare CORP | Stock-Healthcare | 2.04% | — | — | |
| 16 | CAI | Caris Life Sciences Inc | Stock-Other | 2.03% | -0.10% | — | |
| 17 | IRON | Disc Medicine Inc | Stock-Other | 1.87% | -0.91% | — | |
| 18 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.65% | +0.53% | — | |
| 19 | SION | Sionna Therapeutics Inc | Stock-Other | 1.61% | -0.80% | — | |
| 20 | UPB | Upstream Bio Inc | Stock-Other | 1.56% | -0.32% | — | |
| 21 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.38% | — | -53.08% | |
| 22 | ITGR | Integer Holdings CORP | Stock-Healthcare | 1.33% | — | -34.58% | |
| 23 | CGON | Cg Oncology Inc | Stock-Other | 1.32% | -0.03% | -17.97% | |
| 24 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.29% | — | — | |
| 25 | SIBN | Si-bone Inc | Stock-Other | 1.21% | — | -25.09% | |
| 26 | MBX | Mbx Biosciences Inc | Stock-Other | 1.14% | +1.30% | — | |
| 27 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.12% | -0.20% | +10.65% | |
| 28 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.99% | -1.03% | -31.94% | |
| 29 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.89% | +0.04% | NEW | |
| 30 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.83% | -0.04% | +15.02% | |
| 31 | EXK | Exact Sciences CORP | Stock-Materials | 0.81% | — | -10.66% | |
| 32 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.78% | — | — | |
| 33 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.78% | — | — | |
| 34 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.74% | -0.26% | — | |
| 35 | NPCE | Neuropace Inc | Stock-Other | 0.73% | -0.11% | -23.26% | |
| 36 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.72% | -0.16% | +3.19% | |
| 37 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.70% | — | — | |
| 38 | JANX | Janux Therapeutics Inc | Stock-Other | 0.70% | -0.13% | +59.55% | |
| 39 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.66% | — | +6.98% | |
| 40 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.62% | +0.75% | +49.53% | |
| 41 | SCPH | Scpharmaceuticals Inc | Stock-Other | 0.58% | — | — | |
| 42 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.48% | — | — | |
| 43 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.47% | +0.38% | -63.95% | |
| 44 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.46% | — | +71.40% | |
| 45 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.45% | -0.10% | +195.39% | |
| 46 | ✓ | Adc Therapeutics SA | Stock-Other | 0.40% | -0.10% | EXIT | |
| 47 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.39% | +0.11% | -34.60% | |
| 48 | FBRX | Forte Biosciences Inc | Stock-Other | 0.39% | -0.02% | +101.82% | |
| 49 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.36% | -0.07% | EXIT | |
| 50 | KROS | Keros Therapeutics Inc | Stock-Other | 0.34% | -0.02% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CAI | Caris Life Sciences Inc | +2% | NEW | New buy |
| 2 | SPRY | Ars Pharmaceuticals Inc | +1.1% | — | Unchanged |
| 3 | ROIV | Roivant Sciences Ltd. | +0.8% | NEW | New buy |
| 4 | BSX | Boston Scientific CORP | +0.8% | — | Unchanged |
| 5 | UPB | Upstream Bio Inc | +0.7% | — | Unchanged |
| 6 | SION | Sionna Therapeutics Inc | +0.7% | — | Unchanged |
| 7 | EW | Edwards Lifesciences CORP | +0.7% | +11.49% | Add |
| 8 | NTRA | Natera Inc | +0.7% | +8.49% | Add |
| 9 | THC | Tenet Healthcare CORP | +0.6% | — | Unchanged |
| 10 | ALNY | Alnylam Pharmaceuticals Inc | +0.6% | -1.21% | Trim |
| 11 | ISRG | Intuitive Surgical Inc | +0.5% | — | Unchanged |
| 12 | UNH | Unitedhealth Group Inc | +0.5% | +92.00% | Add |
| 13 | VRTX | Vertex Pharmaceuticals Inc | +0.5% | +31.51% | Add |
| 14 | CTMX | Cytomx Therapeutics Inc | +0.5% | NEW | New buy |
| 15 | MBX | Mbx Biosciences Inc | +0.4% | — | Unchanged |
| 16 | SVA | Sinovac Biotech Ltd. | +0.4% | — | Unchanged |
| 17 | SYK | Stryker CORP | +0.4% | — | Unchanged |
| 18 | RAPT | Rapt Therapeutics Inc | +0.3% | NEW | New buy |
| 19 | AVBP | Arrivent Biopharma Inc | +0.3% | — | Unchanged |
| 20 | ✓ | Third Harmonic Bio Inc | +0.3% | — | Unchanged |
| 21 | GPCR | Structure Therapeutics Inc | +0.3% | +49.53% | Add |
| 22 | TRVI | Trevi Therapeutics Inc | +0.3% | +195.39% | Add |
| 23 | FBRX | Forte Biosciences Inc | +0.3% | +101.82% | Add |
| 24 | MLYS | Mineralys Therapeutics Inc | +0.3% | NEW | New buy |
| 25 | ELVN | Enliven Therapeutics Inc | +0.3% | — | Unchanged |
| 26 | CPRX | Catalyst Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 27 | AGIO | Agios Pharmaceuticals Inc | +0.2% | +71.40% | Add |
| 28 | JANX | Janux Therapeutics Inc | +0.2% | +59.55% | Add |
| 29 | ZLAB | Zai Lab Ltd-adr | +0.2% | NEW | New buy |
| 30 | ✓ | Adc Therapeutics SA | +0.2% | -1.02% | Trim |
| 31 | 430 | Terns Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 32 | SCPH | Scpharmaceuticals Inc | +0.2% | — | Unchanged |
| 33 | IRON | Disc Medicine Inc | +0.2% | — | Unchanged |
| 34 | CRVS | Corvus Pharmaceuticals Inc | +0.2% | +3.19% | Add |
| 35 | AZNN | Astrazeneca Plc-spons Adr | +0.2% | NEW | New buy |
| 36 | 2662247D | Iteos Therapeutics Inc | +0.2% | NEW | New buy |
| 37 | URGN | UroGen Pharma Ltd. | +0.2% | NEW | New buy |
| 38 | ASND | Ascendis Pharma A/S | +0.2% | NEW | New buy |
| 39 | ALMS | Alumis Inc | +0.1% | NEW | New buy |
| 40 | ORIC | Oric Pharmaceuticals Inc | +0.1% | +28.47% | Add |
| 41 | JBIO | Jade Biosciences Inc | +0.1% | NEW | New buy |
| 42 | AKRO | Akero Therapeutics Inc | +0.1% | +17.45% | Add |
| 43 | EXK | Exact Sciences CORP | +0.1% | -10.66% | Trim |
| 44 | KROS | Keros Therapeutics Inc | +0.1% | — | Unchanged |
| 45 | ABCL | Abcellera Biologics Inc | +0.1% | -20.00% | Trim |
| 46 | SIBN | Si-bone Inc | +0.1% | -25.09% | Trim |
| 47 | CRBP | Corbus Pharmaceuticals Holdi | +0.1% | — | Unchanged |
| 48 | ✓ | Mural Oncology Pub LTD Co | 0% | NEW | New buy |
| 49 | RPTX | Repare Therapeutics Inc | 0% | — | Unchanged |
| 50 | AXSM | Axsome Therapeutics Inc | 0% | +10.65% | Add |
According to official SEC Form 13F filings, Orbimed Advisors LLC reported a total U.S. public equity portfolio value of $5.4B across 99 disclosed positions in Q2 2025.
During Q2 2025, Orbimed Advisors LLC's top holdings by market value included SVA (8.3%)、BSX (7.5%)、LLY (6.6%). The largest single position, SVA, represented 8.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
CAI
市值: $81.1M
Top Position Liquidated / Trimmed
PFE
前期市值: $110.2M
In Q2 2025, Orbimed Advisors LLC made 82 total portfolio adjustments, initiating 16 new buys, adding to 19 positions, trimming 23 holdings, and fully liquidating 24 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.